Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
18 search results for:

Rosiglitazone/Metformin 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 28-06-2017 | Topic page

    Rosiglitazone_Metformin

  2. 09-08-2022 | Liraglutide (T2DM) | At a glance | Article

    A quick guide to the LEAD trials

    Bodyweight fell by an average of 0.2 kg with liraglutide 1.8 mg and 0.1 kg with placebo, but increased with rosiglitazone.

  3. 05-04-2022 | Medications | At a glance | Article
    At a glance

    Medications for pediatric type 2 diabetes: What’s approved, what’s coming up?

    Metformin Before 2019, only metformin had been formally tested in a randomized trial involving pediatric patients.

    Author:
    Eleanor McDermid
  4. 06-02-2020 | Rosiglitazone | News | Article

    Individual patient data analysis firms up rosiglitazone safety verdict

    An individual patient data meta-analysis confirms the increased heart failure risk associated with rosiglitazone and lends some support to an elevated myocardial infarction risk.

    Author:
    Eleanor McDermid
    Published in:
    BMJ 2020; 368 : l7078
  5. 31-01-2020 | Cardiovascular outcomes | News | Article

    Cardiovascular risks, benefits of different diabetes drugs quantified

    The team found mostly neutral results with sulfonylureas, acarbose and voglibose, nateglinide, bromocriptine, insulin, and metformin, although metformin was associated with numerically lower rates of MACE than comparator treatments.

    Author:
    Claire Barnard
    Published in:
    Lancet Diabetes Endocrinol 2020; doi:10.1016/S2213-8587(19)30422-X Lancet Diabetes Endocrinol 2020; doi:10.1016/S2213-8587(20)30020-6
  6. 13-03-2018 | Adolescents | News | Article

    Data support bariatric surgery for severely obese teens with type 2 diabetes

    Bariatric surgery also resulted in reduced cardiovascular risk markers and improved kidney function whereas treatment with metformin alone or in combination with rosiglitazone had no impact on these variables.

    Published in:
    JAMA Pediatr 2018; Advance online publication
  7. 03-11-2016 | Adolescents | News | Article

    Adiponectin tied to treatment success in adolescents with type 2 diabetes

    During 36 months of treatment (with metformin alone or with rosiglitazone or lifestyle intervention) changes in insulin sensitivity and C-peptide index were similar regardless of ethnicity.

    Published in:
    Diabetes Care 2016; Advance online publication
  8. 10-11-2016 | Type 2 diabetes | Review | Article

    Clinical pharmacokinetics and pharmacodynamics of antihyperglycemic medications in children and adolescents with type 2 diabetes mellitus

    Akhlaghi F et al. Clin Pharmacokinet 2017; 56: 561–571. doi:10.1007/s40262-016-0472-6

  9. 22-06-2018 | Monogenic diabetes | Review | Article

    Advances in the genetics of youth-onset type 2 diabetes

    Todd JN, Srinivasan S, Pollin TI. Curr Diab Rep 2018; 18: 57. doi: 10.1007/s11892-018-1025-1

  10. 15-06-2018 | Semaglutide | Article

    Semaglutide s.c. once-weekly in type 2 diabetes: A population pharmacokinetic analysis

    Carlsson Petri KC et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0458-5

  11. 09-06-2018 | Cardiovascular disorders | Review | Article

    Molecular mechanisms underlying the cardiovascular benefits of SGLT2i and GLP-1RA

    Khat DZ, Husain M. Curr Diab Rep 2018; 18: 45. doi: 10.1007/s11892-018-1011-7

  12. 08-06-2018 | Insulin resistance | Review | Article

    Chronic kidney disease-induced insulin resistance: Current state of the field

    Dave N, Wu J, Thomas S. Curr Diab Rep 2018; 18: 44. doi: 10.1007/s11892-018-1010-8

  13. 05-06-2018 | Cardiovascular outcomes | Review | Article

    Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: A comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials

    Zhuang X et al. Cardiovasc Diabetol 2018; 17: 79. doi: 10.1186/s12933-018-0722-z

  14. 18-05-2018 | Type 2 diabetes | Review | Article

    Combination glucose-lowering therapy plans in T2DM: Case-based considerations

    Blonde L, Dipp S, Cadena D. Adv Ther 2018. doi: 10.1007/s12325-018-0694-0

  15. 04-05-2018 | GLP-1 agonists | Review | Article

    Glucagon-like peptide 1 in health and disease

    Andersen A et al. Nat Rev Endocrinol 2018; Advance online publication. doi: 10.1038/s41574-018-0016-2

  16. 28-04-2018 | Heart failure | Review | Article

    SGLT2 inhibition and heart failure: Current concepts

    Custodio JS et al. Heart Fail Rev 2018; 23: 409–418. doi: 10.1007/s10741-018-9703-2

  17. 08-09-2017 | Latent autoimmune diabetes of adulthood | Review | Article

    Adult-onset autoimmune diabetes: Current knowledge and implications for management

    Nat Rev Endocrinol 2017; 13: 674–686. doi: 10.1038/nrendo.2017.99

    Author:
    Raffaella Buzzetti, Simona Zampetti, Ernesto Maddaloni
  18. 31-07-2017 | Diabetes prevention | Review | Article

    Pharmaceutical interventions for diabetes prevention in patients at risk

    Chatterjee S, Davies M, Khunti K. Am J Cardiovasc Drugs 2017; 1: 13–24. doi: 10.1007/s40256-017-0239-y

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.